title: Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
abstract: Angelman syndrome (AS) is a severe neurodevelopmental disorder that results from loss of function of the maternal ubiquitin protein ligase E3A (UBE3A) allele. Due to neuron-specific imprinting, the paternal UBE3A copy is silenced. Previous studies in murine models have demonstrated that strategies to activate the paternal Ube3a allele are feasible; however, a recent study showed that pharmacological Ube3a gene reactivation in adulthood failed to rescue the majority of neurocognitive phenotypes in a murine AS model. Here, we performed a systematic study to investigate the possibility that neurocognitive rescue can be achieved by reinstating Ube3a during earlier neurodevelopmental windows. We developed an AS model that allows for temporally controlled Cre-dependent induction of the maternal Ube3a allele and determined that there are distinct neurodevelopmental windows during which Ube3a restoration can rescue AS-relevant phenotypes. Motor deficits were rescued by Ube3a reinstatement in adolescent mice, whereas anxiety, repetitive behavior, and epilepsy were only rescued when Ube3a was reinstated during early development. In contrast, hippocampal synaptic plasticity could be restored at any age. Together, these findings suggest that Ube3a reinstatement early in development may be necessary to prevent or rescue most AS-associated phenotypes and should be considered in future clinical trial design.
authors: Sara
authors: S
authors: Silva-Santos
authors: Geeske M
authors: GM
authors: van Woerden
authors: Caroline F
authors: CF
authors: Bruinsma
authors: Edwin
authors: E
authors: Mientjes
authors: Mehrnoush Aghadavoud
authors: MA
authors: Jolfaei
authors: Ben
authors: B
authors: Distel
authors: Steven A
authors: SA
authors: Kushner
authors: Ype
authors: Y
authors: Elgersma
mesh_terms: D000367:Age Factors; D017204:Angelman Syndrome / Q000196:embryology / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D000818:Animals; D001007:Anxiety / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D002531:Cerebellum / Q000196:embryology / Q000503:physiopathology; D002540:Cerebral Cortex / Q000196:embryology / Q000503:physiopathology; D004195:Disease Models, Animal; D004827:Epilepsy / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D005260:Female; D018507:Gene Expression Regulation, Developmental; D005813:Genes, Synthetic; D018392:Genomic Imprinting; D006624:Hippocampus / Q000196:embryology / Q000503:physiopathology; D008297:Male; D051379:Mice; D009069:Movement Disorders / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D009473:Neuronal Plasticity; D010641:Phenotype; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics; D013239:Stereotyped Behavior / Q000502:physiology; D013629:Tamoxifen / Q000494:pharmacology; D044767:Ubiquitin-Protein Ligases / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics / Q000502:physiology*
chemical_list: D011993:Recombinant Fusion Proteins; D013629:Tamoxifen; C502429:Ube3a protein, mouse; D044767:Ubiquitin-Protein Ligases